Hutchison MediPharma reported its lead drug candidate, HMPL-004, met all endpoints in a Phase IIb clinical trial in patients with mild-to-moderate active Ulcerative Colitis. Last summer, the company announced that early data showed HMPL-004 was effective in another Phase II trial, this one conducted in patients with Crohn’s disease. HMPL-004 is a proprietary oral compound that is extracted from a China herb and retards inflammation through a novel mechanism. More details...

Stock Symbol: (AIM: CHM)